Journal of Psychopharmacology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Register here to gain access to SAGE's 500+ Journals Online

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0269881105057002v1
0269881105057002v2
20/3/335    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (11)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thornton, A. E.
Right arrow Articles by Honer, W. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thornton, A. E.
Right arrow Articles by Honer, W. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
This version was published on May 1, 2006
Journal of Psychopharmacology, Vol. 20, No. 3, 335-346 (2006)
DOI: 10.1177/0269881105057002

Reviews

The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review

Allen E. Thornton

Department of Psychology, Simon Fraser University, Burnaby, B.C., Canada V5A 1S6, Centre for Complex Disorders, Vancouver General Hospital, Vancouver, B.C., Canada V52 1M9 and Department of Medicine and Research, Riverview Hospital, Coquitlam, B.C., Canada, V3C 4J2

Jared X. Van Snellenberg

Amir A. Sepehry

Department of Psychology, Simon Fraser University, Burnaby, B.C., Canada, V54 1S6

William G. Honer

Department of Psychiatry, University of British Columbia, Vancouver, B.C., Centre for Complex Disorders, Vancouver General Hospital, Vancouver, B.C. and Department of Medicine and Research, Riverview Hospital, Coquitlam, B.C. Canada V3C 4J2

This meta-analytic review examines the ef.cacy of antipsychotic medications in ameliorating schizophrenia-related long-term memory (LTM) impairments. Twenty-three studies were reviewed that compared schizophrenia spectrum patients treated (a) with atypical versus typical antipsychotic medications, or (b) with various atypical treatments. In 17 atypical versus typical trials aggregating 939 participants, superior overall (verbal and nonverbal) LTM was detected in patients assigned to atypical trials. However, this difference was small (effect size estimate (ES) 0.17; 95% Con.dence Interval (CI) 0.04 to 0.31) and speci.c to certain atypical treatments. Relative to typical antipsychotic trials, LTM superiority was marginally signi.cant for risperidone trials (ES 0.20; 95% CI 0.03 to 0.44) and signi.cant for olanzapine trials (ES 0.29; 95% CI 0.08 to 0.49). In contrast, clozapine trials did not produce a LTM advantage over typical trials (ES 0.06; 95% CI 0.35 to 0.23). Due to the lack of available studies, the effect of quetiapine was indeterminate. Direct comparison between atypical trials revealed a similar effect pattern. A marginally signi.cant superiority in overall LTM was detected for risperidone and olanzapine compared to clozapine (ES 0.28; 95% CI 0.04 to 0.59), which reached signi.cance for verbal LTM (ES 0.36; 95% CI 0.04 to 0.67). Finally, the bene.cial impact of antipsychotic medications emerged as a function of differences in the anticholinergic properties of the treatment arms being compared.

Key Words: schizophrenia • memory • cognition • atypical antipsychotic • pharmacotherapy • meta-analysis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
M. J. Millan, F. Loiseau, A. Dekeyne, A. Gobert, G. Flik, T. I. Cremers, J.-M. Rivet, D. Sicard, R. Billiras, and M. Brocco
S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: III. Actions in Models of Therapeutic Activity and Induction of Side Effects
J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1212 - 1226.
[Abstract] [Full Text] [PDF]

Home page
 Schizophr BullHome page
W. S. Stone and L. J. Seidman
Toward a Model of Memory Enhancement in Schizophrenia: Glucose Administration and Hippocampal Function
Schizophr Bull, January 1, 2008; 34(1): 93 - 108.
[Abstract] [Full Text] [PDF]

Home page
 Soc Cogn Affect NeurosciHome page
T. D. Wager, M. Lindquist, and L. Kaplan
Meta-analysis of functional neuroimaging data: current and future directions
Soc Cogn Affect Neurosci, June 1, 2007; 2(2): 150 - 158.
[Abstract] [Full Text] [PDF]

Home page
 J Am Acad Psychiatry LawHome page
S. K. Erickson, J. R. Ciccone, S. B. Schwarzkopf, J. S. Lamberti, and M. J. Vitacco
Legal Fallacies of Antipsychotic Drugs
J Am Acad Psychiatry Law, June 1, 2007; 35(2): 235 - 246.
[Abstract] [Full Text] [PDF]

Home page
 Schizophr BullHome page
R. E. Gur, M. E. Calkins, R. C. Gur, W. P. Horan, K. H. Nuechterlein, L. J. Seidman, and W. S. Stone
The Consortium on the Genetics of Schizophrenia: Neurocognitive Endophenotypes
Schizophr Bull, January 1, 2007; 33(1): 49 - 68.
[Abstract] [Full Text] [PDF]